MHMegan Hanrahan

Megan Hanrahan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megan Hanrahan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acceptability of Wearable Digital Devices for Remote Continuous Mobility Monitoring in People With Parkinson Disease and Carers: Qualitative Study

    by Megan Hanrahan, Jack Lumsdon, Cameron Wilson, Essa Bhadra, Alison Keogh, Tova Gur-Arieh, Alastair Noyce, Alison Yarnall, Lynn Rochester, Ríona Mc Ardle, et al.

    Background: Parkinson disease (PD) impairs mobility and motor function, making accurate mobility assessment important for effective management and treatment planning. Traditional clinical assessments often rely on periodic clinical evaluations, which may not capture day-to-day symptom fluctuations. Wearable devices offer a promising alternative with continuous, objective tracking of mobility (eg, gait). However, although these tools provide valuable insights for patients and clinicians, their successful implementation depends on their acceptability to users. Objective: This study aimed to explore the acceptability of wearable devices for remote continuous mobility monitoring in PD from the perspectives of people with PD and informal carers. Methods: This international qualitative study used purposive sampling to recruit a diverse sample of 72 people with PD and 20 informal carers from the United Kingdom, Ireland, Belgium, Germany, Spain, and the United States. Participants were recruited between June 2023 and February 2026 through multiple community-based routes. One-to-one semistructured interviews, conducted online, via telephone, or in person, explored views on wearable devices for digital mobility assessment. Interview data were analyzed using Braun and Clarke’s 6-phase reflexive thematic analysis. Results: Most people with PD were generally open to wearable monitoring when it could capture motor fluctuations between “on” and “off” periods that were difficult to convey during clinical appointments, reduce reliance on memory, provide objective evidence to support treatment and medication discussions and self-advocacy, and track changes in mobility over time, which some felt could be reassuring. Acceptability depended on devices having a clear purpose, requiring minimal effort, and being easy to use. Tremor, reduced dexterity, and “off” periods could make fastening straps, navigating menus, and charging devices difficult. Carers valued wearable monitoring for the reassurance and safety it offered, particularly fall detection, and for support with both clinical and everyday decision-making but emphasized that devices must operate passively and integrate into daily caregiving without adding burden. Conclusions: Wearable mobility monitoring was generally acceptable to people with PD and carers when it offered clear clinical value, fit easily into everyday life, and provided reassurance that remote monitoring would complement rather than replace clinical care. As PD mobility was experienced as a shared concern within the care relationship, the value of monitoring depended on how well it supported the wider care dyad rather than the person with PD alone. These findings suggest that successful implementation will require co-design with people with PD and carers, alongside thoughtful clinical integration, to ensure that wearable technologies are both acceptable and effective in practice.

  • Open Access

    Meaningful digital mobility outcomes for people with Parkinson's disease: Insights grounded in diverse lived experience

    by Jack Lumsdon, Ríona Mc Ardle, Megan Hanrahan, Alison Keogh, Cameron Wilson, Tova Gur Arieh, Alastair J Noyce, Essa Bhadra, Johanna Graeber, Lova Hulst, et al.

    Background: Digital mobility outcomes (DMOs) have been cited as potential clinical endpoints for trials in Parkinson's disease (PD). Current evidence from the Mobilise-D consortium suggests that selected DMOs are technically valid, with emerging research on their clinical validity. However, regulatory qualification of DMOs requires additional evidence of their meaningfulness to people with PD. Objective: To identify meaningful DMOs by understanding how mobility symptoms impact aspects of health that matter to people with PD. Methods: Purposive sampling recruited a diverse sample of people with PD to participate in semi-structured interviews. Content analysis identified frequent and bothersome mobility symptoms and their impacts on meaningful aspects of health. Twelve experts mapped meaningful symptoms to relevant DMOs through a nominal group consensus. Results: Seventy-two people with PD participated, inclusive of under-served groups: ethnic minorities (14%) or LGBTQIA + backgrounds (14%), in older age (3%) or with young-onset PD (13%), living rurally (31%) or in a deprived area (19%). Shuffling gait, bradykinesia and balance issues were the most frequent symptoms, and the most bothersome and impactful on meaningful aspects of health (i.e., activities of daily living, life-space mobility, emotional wellbeing) among participants who experienced them. Less frequent, but still highly bothersome and impactful symptoms included freezing of gait, fatigue and weakness. Expert consensus suggested that walking speed, stride length and turn duration were the most relevant DMOs to reflect these meaningful symptoms. Conclusion: Findings offer an inclusive, meaningful framework for digital assessment of mobility in PD, grounded in lived experience and consistent with regulatory guidance.

  • Open Access

    Impact of Mobility Loss on Independence and Psychosocial Wellbeing in People With Parkinson’s Disease and Carers: A Meta-Ethnography

    by Megan Hanrahan, Cameron Wilson, Lynn Rochester, Alison Keogh, Ríona Mc Ardle, Katie Brittain

    Background: Mobility impairments in Parkinson’s disease (PD) significantly impact individuals’ physical health, independence, and psychosocial wellbeing. In this review, mobility loss is used to refer to altered or impaired mobility (eg, reduced gait, balance difficulties, freezing of gait), rather than a complete loss of mobility. These changes affect daily functioning and quality of life. Carers also experience significant burden as they manage mobility issues. Understanding the implications of mobility loss in PD is essential for improving support for both people with PD and carers. This review explores impact of mobility loss on perceived independence and psychosocial wellbeing in people with PD and carers, providing deeper insight into the broader emotional and social consequences of the condition. Methods: A systematic search of six health databases (Medline, Embase, PsycInfo, CINAHL, Scopus, Web of Science) was conducted using key terms related to mobility loss, independence, and psychosocial wellbeing in PD. Studies were included if they employed qualitative methods to explore experiences of mobility from people with PD and/or carers. The methodological quality of studies was assessed using the NICE qualitative checklist, and reporting adhered to PRISMA guidelines. A meta-ethnographic approach was used to extract key themes and construct a comprehensive understanding of the findings. Results: Five key themes emerged: the struggle for independence and associated self-esteem, navigating personal relationships, perceived stigmatisation and social isolation, resilience and adaptation, and impact of mobility on carer wellbeing. Discussion: Findings highlight the need for comprehensive support systems that address the challenges of mobility loss in PD. Wearable technology presents a promising solution for personalised interventions. Future research should explore diverse populations of people with PD and include formal carers to develop a more holistic perspective of mobility-related challenges in PD caregiving.


  • Open Access

    Acceptability and feasibility of shared medical appointments to support self-management of anxiety and depression in primary care in England: a qualitative study of service user/patient perspectives

    by Megan Hanrahan, Fiona Graham, Mei Yee Tang

    Objective: Shared medical appointments (SMAs) are an innovative care delivery method that provides delivery of clinical care while also supporting self-management. Their usefulness for mental health conditions has only briefly been explored, though early evidence demonstrates their utility for supporting mental health management. Therefore, this study set out to better understand the views that adults with anxiety and depression have towards SMAs as a way of receiving care to support self-management in primary care. Design and methods: A qualitative study using 1:1 semi-structured interviews which were analysed thematically following Braun and Clarke’s six-phase reiterative process. We employed a deductive, theory-informed approach to thematically analyse the data. Participants: The final sample consisted of 17 predominantly White ethnic adults with a clinical diagnosis of anxiety and/or depression from five different regions in England. Participants represented a broad age group (22–74 years) and a range of socioeconomic backgrounds. Results: Three main themes were established: (1) motivation to attend an SMA, (2) barriers and challenges to SMA engagement and (3) implementation preferences. The concept of SMAs was largely acceptable to participants, although participants reported several factors that would influence their decision to attend an SMA. Participants held some reservations but were on the whole receptive to the idea. The main benefits reported were peer support, support for self-management and quicker access to care. Drawbacks reported included risks to patient confidentiality, negative impact on emotional well-being and the unsuitability of the group setting for some patients. Some salient preferences identified included face-to-face/hybrid delivery formatting and mental health specialist involvement. Conclusions: SMAs in primary care to support anxiety and depression self-management would be acceptable to patients, contingent on the mode of delivery of the SMAs. Future acceptability research should explore SMA appropriateness for diverse patient populations of different ethnic backgrounds, to inform their potential wider roll-out in English primary care.